Last reviewed · How we verify
CombAct-HIB®
CombAct-HIB is a combination vaccine that provides immunization against Haemophilus influenzae type b (Hib) by stimulating antibody production against the bacterial polysaccharide capsule.
CombAct-HIB is a combination vaccine that provides immunization against Haemophilus influenzae type b (Hib) by stimulating antibody production against the bacterial polysaccharide capsule. Used for Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | CombAct-HIB® |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains Hib polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune responses. This conjugate design improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive Hib disease.
Approved indications
- Prevention of invasive disease caused by Haemophilus influenzae type b in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CombAct-HIB® CI brief — competitive landscape report
- CombAct-HIB® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI